Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 34 of 34 entries
View as:

Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease

Phase: N/A Priority: Normal
NCT ID: NCT02648347 Org: User:
Start: 12/31/15 End: 07/31/20 Due: 07/31/21

Drug-Drug Interaction Study of Vadadustat With Digoxin, Adefovir and Furosemide

Phase: N/A Priority: Normal
NCT ID: NCT03801759 Org: User:
Start: 07/20/18 End: 09/30/18 Due: 09/30/19

A Study in Evaluating Bioequivalence of Test and Reference Vadadustat 450 MG and 150 MG Tablets and to Determine Food Effect on the 450 MG Tablet

Phase: N/A Priority: Normal
NCT ID: NCT03657290 Org: User:
Start: 08/03/18 End: 10/16/18 Due: 10/16/19

Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-Stimulating Agents

Phase: N/A Priority: Normal
NCT ID: NCT05082584 Org: User:
Start: 01/31/25 End: 10/31/26 Due: 10/31/27

Study to Assess the Safety and Pharmacokinetics of AKB-6548 in Participants With Chronic Kidney Disease (CKD), Stages 3 and 4

Phase: N/A Priority: Normal
NCT ID: NCT04707573 Org: User:
Start: 07/08/10 End: 09/24/10 Due: 09/24/11

Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)

Phase: N/A Priority: Normal
NCT ID: NCT04313153 Org: User:
Start: 05/27/20 End: 06/22/22 Due: 06/22/23

Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects

Phase: N/A Priority: Normal
NCT ID: NCT04707768 Org: User:
Start: 06/18/21 End: 01/30/23 Due: 01/30/24

A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)

Phase: N/A Priority: Normal
NCT ID: NCT03254485 Org: User:
Start: 11/07/17 End: 08/19/19 Due: 08/19/20

Study to Evaluate the Effect of Rabeprazole on the Pharmacokinetics of Vadadustat

Phase: N/A Priority: Normal
NCT ID: NCT03789032 Org: User:
Start: 10/03/18 End: 11/19/18 Due: 11/19/19